.Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BX03_Piracetam.Piracetam .Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BX03_Piracetam.Piracetam| name: | Piracetam |
| ATC code: | N06BX03 | route: | oral |
| n-compartments | 1 |
Piracetam is a nootropic agent, classified as a cyclic derivative of GABA, used to treat cognitive impairment and myoclonus. It is not FDA approved in the United States but is approved in some European and other countries for cognitive disorders, vertigo, and myoclonus.
Pharmacokinetics reported in healthy adult volunteers of both sexes after oral administration.
Rhee, SJ, et al., & Lee, SK (2017). Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy research 132 8–14. DOI:10.1016/j.eplepsyres.2017.02.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28279893
Hernández-Mitre, MP, et al., & Milán-Segovia, RDC (2020). Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. Journal of pharmaceutical sciences 109(6) 2070–2078. DOI:10.1016/j.xphs.2020.02.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32113977
Pigeolet, E, et al., & Stockis, A (2007). Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clinical pharmacokinetics 46(6) 503–512. DOI:10.2165/00003088-200746060-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17518509